These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 22226626

  • 1. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.
    Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J.
    Lung Cancer; 2012 Jun; 76(3):380-6. PubMed ID: 22226626
    [Abstract] [Full Text] [Related]

  • 2. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J, Liang X, Zhou X, Huang R, Chu Z.
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [Abstract] [Full Text] [Related]

  • 3. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G.
    J Clin Oncol; 2011 Aug 01; 29(22):2965-71. PubMed ID: 21709202
    [Abstract] [Full Text] [Related]

  • 4. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF.
    J Clin Oncol; 2012 Jun 10; 30(17):2055-62. PubMed ID: 22547591
    [Abstract] [Full Text] [Related]

  • 5. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ, Belani CP.
    Cancer; 2008 Aug 01; 113(3):542-6. PubMed ID: 18512224
    [Abstract] [Full Text] [Related]

  • 6. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX, Chen XB.
    Ai Zheng; 2002 Apr 01; 21(4):412-5. PubMed ID: 12452023
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G, Uzzan B, Nicolas P, Valeyre D, Sebbane G, Morere JF.
    Crit Rev Oncol Hematol; 2012 Dec 01; 84(3):340-9. PubMed ID: 22534083
    [Abstract] [Full Text] [Related]

  • 8. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ.
    J Clin Oncol; 2008 Jan 20; 26(3):468-73. PubMed ID: 18202422
    [Abstract] [Full Text] [Related]

  • 9. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS.
    Cancer; 2002 Sep 15; 95(6):1265-73. PubMed ID: 12216094
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL, Gregorc V, Cordio S, Bencardino KB, Schipani S, Cozzarini C, Bordonaro R, Villa E.
    Lung Cancer; 2004 May 15; 44(2):231-9. PubMed ID: 15084388
    [Abstract] [Full Text] [Related]

  • 12. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
    Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C.
    J Clin Oncol; 2009 Apr 10; 27(11):1836-43. PubMed ID: 19273711
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA, Garfield DH, Khan MM, Look RM, Boehm KA, Asmar L.
    Lung Cancer; 2005 Jan 10; 47(1):111-20. PubMed ID: 15603861
    [Abstract] [Full Text] [Related]

  • 16. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L.
    Lung Cancer; 2004 Oct 10; 46(1):87-98. PubMed ID: 15364136
    [Abstract] [Full Text] [Related]

  • 17. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA.
    Cancer; 2003 Aug 15; 98(4):779-88. PubMed ID: 12910523
    [Abstract] [Full Text] [Related]

  • 18. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
    Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA.
    Eur J Cancer; 2014 Mar 15; 50(4):706-12. PubMed ID: 24360368
    [Abstract] [Full Text] [Related]

  • 19. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
    Ichiki M, Kawasaki M, Takayama K, Ninomiya K, Kuba M, Iwami F, Miyazaki N, Oishi K, Takeo S, Aizawa H, Nakanishi Y.
    Cancer Chemother Pharmacol; 2006 Sep 15; 58(3):368-73. PubMed ID: 16395589
    [Abstract] [Full Text] [Related]

  • 20. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR.
    Cancer; 2003 May 15; 97(10):2480-6. PubMed ID: 12733147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.